ArticleInternational journal of nanomedicine2014
Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes.
Article in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Baicalin: A comprehensive review of its molecular mechanisms and pharmacological activities.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Integrating Traditional Chinese Medicine and Nanotechnology for Enhanced Management of Anti-Tumor Drug Toxicity.Molecules (Basel, Switzerland) · 2026Review
- PEGylated liposomes enhance the pharmacokinetics, biodistribution, anticancer efficacy, and safety of Kaempferol, a phytomolecule enrolled in clinical trials.Scientific reports · 2026Article
- Baicalin: Natural Sources, Extraction Techniques, and Therapeutic Applications Against Bacterial Infections.Molecules (Basel, Switzerland) · 2025Review
- Baicalin as a potential candidate for treating systemic sclerosis.Inflammopharmacology · 2025Review
- Review
- Review
- Baicalein, a natural flavonoid in gastrointestinal cancers treatment: recent trends and future perspectives.Medical oncology (Northwood, London, England) · 2024Review
- Baicalein Long-Circulating Liposomes Improve Histological and Functional Outcomes After Traumatic Brain Injury.Advances in pharmacological and pharmaceutical sciences · 2024Article
- Pharmacological mechanisms by which baicalin ameliorates cardiovascular disease.Frontiers in pharmacology · 2024Review
- Immuno-modulatory role of baicalin in atherosclerosis prevention and treatment: current scenario and future directions.Frontiers in immunology · 2024Review
- Article
- Sodium Alginate/Chitosan-Coated Liposomes for Oral Delivery of Hydroxy-α-Sanshool: In Vitro and In Vivo Evaluation.Pharmaceutics · 2023Article
- The protective effects of baicalin for respiratory diseases: an update and future perspectives.Frontiers in pharmacology · 2023Review
- The Flavonoid Components ofCurrent topics in medicinal chemistry · 2023Review
- Antiviral plant-derived natural products to combat RNA viruses: Targets throughout the viral life cycle.Letters in applied microbiology · 2022Review
- Liver-Targeted Nanoparticles Facilitate the Bioavailability and Anti-HBV Efficacy of Baicalin In Vitro and In Vivo.Biomedicines · 2022Article
- Investigating Polyphenol Nanoformulations for Therapeutic Targets against Diabetes Mellitus.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Approaches to Address PK-PD Challenges of Conventional Liposome Formulation with Special Reference to Cancer, Alzheimer's, Diabetes, and Glaucoma: An Update on Modified Liposomal Drug Delivery System.Current drug metabolism · 2022Review
- Baicalin Inhibits NLRP3 Inflammasome Activity Via the AMPK Signaling Pathway to Alleviate Cerebral Ischemia-Reperfusion Injury.Inflammation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baicalin (BA) is a major constituent of Scutellaria baicalensis Georgi, a medicinal herb. Previous pharmacokinetic studies of BA showed its low oral bioavailability. The aim of the present study was to develop a novel BA-loaded liposome (BA-LP) to enhance oral bioavailability. BA-LP, composed of BA, Tween(®) 80, Phospholipon(®) 90H, and citric acid at weight ratio of 96/50/96/50, respectively, was prepared by the effervescent dispersion technique and characterized in terms of morphology, size, zeta potential, encapsulation efficiency, and the in vitro release. Pharmacokinetics and biodistribution studies were carried out in rats after oral administration of BA-LP and a carboxymethyl cellulose suspension containing BA (BA-CMC) as a control. BA-LP exhibited a spherical shape by transmission electron microscopy observation. BA-LP had a mean particle size of 373±15.5 nm, zeta potential of -20.1±0.22 mV, and encapsulation efficiency of 82.7%±0.59%. The BA-LP showed a sustained-release behavior, and the in vitro drug-release kinetic model fit well with the Weibull distribution equation: lnln (1/(1-Q)) =0.609 lnt -1.230 (r=0.995). The oral bioavailability and the peak concentration of the BA-LP was threefold and 2.82-fold that of BA-CMC, respectively. The in vivo distribution results indicated that drug concentrations were significantly increased in the liver, kidney, and lung in the case of BA-LP, which were 5.59-fold, 2.33-fold, and 1.25-fold higher than those of BA-CMC, respectively. In conclusion, the study suggested that BA-LP might be a potential oral drug delivery system to improve bioavailability of BA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.